<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Boltz, Kathy</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Reck, Martin</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">ASSESS</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2015-05-19 09:31:56</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">7-8</style></pages><abstract><style  face="normal" font="default" size="100%">EGFR mutations can be analyzed with circulating tumor DNA, with an overall concordance of EGFR mutation status of 89%. The low positive predictive value of 78% was likely due to false-negative tumor samples using less sensitive methodologies such as DNA sequencing or pyrosequencing, and it increased to 93% when highly sensitive methods such as the QIAGEN Therascreen RGQ PCR kit was used for both tissue/cytology samples and plasma samples.</style></abstract><number><style face="normal" font="default" size="100%">8</style></number><volume><style face="normal" font="default" size="100%">15</style></volume></record></records></xml>